Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Sindall Group Regulatory News (MGNS)

Share Price Information for Morgan Sindall Group (MGNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,425.00
Bid: 2,390.00
Ask: 2,405.00
Change: 0.00 (0.00%)
Spread: 15.00 (0.628%)
Open: 2,435.00
High: 2,435.00
Low: 2,390.00
Prev. Close: 2,425.00
MGNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Voting Update

4 Sep 2023 12:51

RNS Number : 3096L
Morgan Sindall Group PLC
04 September 2023
 

Morgan Sindall Group plc

Legal Entity Identifier (LEI) number: 2138008339ULDGZRB345

 

4 September 2023

Morgan Sindall Group plc ("the Company")

 

Update on response to 2023 AGM voting outcome

 

At our Annual General Meeting ('AGM') held on 4 May 2023, resolution 3 (Approval of the Directors' Remuneration Policy) was supported by a large majority of shareholders but received less than 80% support overall.

 

In advance of the 2023 AGM, the Remuneration Committee (the 'Committee') undertook a detailed engagement with the Company's largest shareholders in relation to the remuneration proposals, and had amended the final Remuneration Policy design in response to feedback received. Following the 2023 AGM, the Committee reached out to the Company's largest shareholders to continue the dialogue and listen to their views - and in particular to understand why those who either abstained or voted against the Directors' Remuneration Policy ('the 'Policy') had done so.

 

The Committee received responses from eight investors, the majority of whom reconfirmed support for the Policy and the management team. 

 

One shareholder raised the annual bonus deferral requirement and 2nd-year phasing down of the post-employment shareholding requirement as their reason for not supporting the resolution. In both cases the Committee is comfortable that its current approach supports appropriate alignment of executive and shareholder interests. In respect of the annual bonus deferral requirement, the Committee also considers this requirement appropriate given the current shareholdings of incumbent Executive Directors. However, the Committee will reconsider both of these Policy design features as part of the next Policy review.

 

The Committee also received feedback from two shareholders that their voting had reflected the 'against' recommendation from one of the major proxy voting agencies, which itself was primarily a result of the simultaneous increases to the Policy headroom available under the annual bonus and LTIP schemes. On this matter, the Committee maintains its view that the Policy should be sufficiently flexible to last for a full triennial review period rather than needing to revert to shareholders to seek incremental changes, and reiterates its commitment to write out to major shareholders in advance of using the increased maximum opportunities under either of the variable incentives.

 

Another shareholder requested that the Committee provide a full explanation in its Remuneration Report of the rationale for the adoption of any increase to the executive directors' incentive opportunities in future years, particularly in relation to the achievement of key strategic objectives, and this feedback is consistent with the current thinking of the Committee.

 

The Committee continues to be grateful for the feedback received and the two-way engagement with major shareholders. Given overall majority support was obtained for the Policy resolution, it is not proposed to make any further changes to the approach to remuneration that was set out in the 2022 Annual Report. The Company will, however, continue to keep the Policy under review over the coming years and welcomes ongoing dialogue with shareholders and proxy advisers.

 

 

Enquiries:

Clare Sheridan, Company Secretary +44 (0) 20 7307 9200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZLFBXKLEBBF
Date   Source Headline
13th May 20209:00 amRNSAdditional Listing
7th May 20201:30 pmRNSResult of AGM
7th May 20207:00 amRNSAGM Trading Update
1st May 202010:54 amRNSTotal Voting Rights
1st May 202010:37 amRNSChange in Director's details
27th Apr 202010:40 amRNSDisclosure of rights attached to equity shares
20th Apr 20201:10 pmRNSBlock listing Interim Review
2nd Apr 20202:57 pmRNSAnnual Financial Report
1st Apr 202012:08 pmRNSTotal Voting Rights
25th Mar 20207:00 amRNSCOVID-19 Update
11th Mar 20203:45 pmRNSHolding(s) in Company
11th Mar 20208:30 amRNSAdditional Listing
9th Mar 20202:33 pmRNSHolding(s) in Company
9th Mar 20202:13 pmRNSDirector/PDMR Shareholding
3rd Mar 20202:14 pmRNSHolding(s) in Company
2nd Mar 20204:15 pmRNSDirector/PDMR Shareholding
2nd Mar 20204:08 pmRNSDirector/PDMR Shareholding
2nd Mar 20203:19 pmRNSTotal Voting Rights
27th Feb 20202:02 pmRNSHolding(s) in Company
27th Feb 20201:48 pmRNSHolding(s) in Company
27th Feb 20201:39 pmRNSHolding(s) in Company
27th Feb 202010:35 amRNSDirector/PDMR Shareholding
24th Feb 20205:45 pmRNSSophos Group
20th Feb 20207:00 amRNSFinal Results
3rd Feb 20204:20 pmRNSTotal Voting Rights
31st Jan 20203:44 pmRNSHolding(s) in Company
29th Jan 20204:18 pmRNSHolding(s) in Company
24th Jan 20203:25 pmRNSHolding(s) in Company
16th Jan 20207:00 amRNSDirectorate Change
9th Jan 20207:00 amRNSNotice of Results
7th Jan 20204:39 pmRNSHolding(s) in Company
2nd Jan 20208:30 amRNSTotal Voting Rights
21st Nov 20199:21 amRNSDirector/PDMR Shareholding
20th Nov 201911:43 amRNSAdditional Listing
18th Nov 20199:48 amRNSAppointment to c£650m Slough scheme
18th Nov 20197:00 amRNSSenior Management Forum
11th Nov 201912:05 pmRNSHolding(s) in Company
11th Nov 201910:25 amRNSDirector/PDMR Shareholding
6th Nov 20197:00 amRNSTrading Update
1st Nov 20191:58 pmRNSTotal Voting Rights
21st Oct 201910:07 amRNSBlock listing Interim Review
8th Oct 20194:37 pmRNSPrice Monitoring Extension
2nd Oct 20194:08 pmRNSHolding(s) in Company
1st Oct 201910:19 amRNSTotal Voting Rights
3rd Sep 201911:30 amRNSAdditional Listing
2nd Sep 20192:49 pmRNSTotal Voting Rights
13th Aug 20193:34 pmRNSHolding(s) in Company
7th Aug 20197:00 amRNSHalf-year Report
1st Aug 201910:08 amRNSTotal Voting Rights
30th Jul 20194:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.